[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qurient Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100603567","phase-1-a-study-to-evaluate-adrixetinib-q702-in-adults-with-active-chronic-graft-versus-host-disease-100603567",false,"NCT07138196","A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease","A Phase 1b, Open-label Dose Escalation Study to Evaluate the Safety, Pharmacodynamic, Pharmacokinetic and Preliminary Efficacy of Q702 in Subjects With Relapsed or Refractory Active Chronic Graft-versus-Host Disease (cGVHD)","Inclusion Criteria:\n\n1. Subjects who are allogeneic HSCT recipients with moderate or severe active cGVHD requiring systemic immune suppression.\n2. Subjects with relapsed or refractory active cGVHD who have progressed after all available standard of care treatments.\n3. Subject must have documented progressive disease as defined by the NIH 2014 consensus criteria, in terms of either organ specific algorithm or global assessment, or active, symptomatic cGVHD for which the treating physician believes that a new line of systemic therapy is required.\n4. Adequate organ and bone marrow functions.\n5. Karnofsky Performance Scale of ≥ 60.\n\nExclusion Criteria:\n\n1. Exposure to CSF1R inhibitor therapy for any indication after allogeneic transplant.\n2. Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of relapse of the underlying cancer.\n3. Diagnosed with another malignancy (other than malignancy for which transplant was performed) within 3 years of enrollment.\n4. Female subject who is pregnant or breastfeeding.\n5. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).",[26],"Chronic Graft-Versus-Host Disease","RECRUITING","2025-12-24",{"date":30,"type":31},"2025-12-30","ACTUAL",{"date":33,"type":31},"2025-12-23",{"date":35,"type":20},"2029-10-31",{"name":37,"class":38},"Qurient Co., Ltd.","INDUSTRY",8,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100469537","phase-1-highly-selective-cdk7-inhibitor-q901-in-selected-advanced-solid-tumors-100469537","NCT05394103","Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors","A Phase 1\u002F2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901Administered Via Intravenous Infusion as Monotherapy and in Combination With Pembrolizumab in Adult Patients With Selected Advanced Solid Tumors With Cohort Expansions at the Recommended Phase 2 Dose","Inclusion Criteria:\n\n* Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy that confers clinical benefit\n* Measurable disease per RECIST v 1.1\n* ECOG performance status 0,1 or 2\n* Life expectancy of at least 3 months\n* Age ≥ 18 years\n* Signed, written IRB-approved informed consent form\n\nExclusion Criteria:\n\n* New York Heart Association Class III or IV cardiac disease, or myocardial infarction, severe unstable angina, coronary\u002Fperipheral artery bypass graft, congestive heart failure within the past 6 months\n* Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of \\>470 msec (females) and \\>450 msec (males)\n* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy\n* Active, poorly controlled autoimmune or inflammatory diseases",{"count":48,"type":20},130,[23,50],"PHASE2","Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab",[53,54],"Advanced Cancer","Metastatic Cancer","2025-08-13",{"date":57,"type":31},"2025-08-17",{"date":59,"type":31},"2022-08-30",{"date":61,"type":20},"2026-08-30",{"name":37,"class":38},11,""]